セッション

Phase 1 study of Venetoclax (VEN) in Japanese (JPN) patients (Pts) with hematologic malignancies

[演者] Noriko Fukuhara:1
[著者] Kiyohiko Hatake:2, Kazuhito Yamamoto:3, Shigeru Kusumoto:4, Koji Izutsu:5, Ilseung Choi:6, Hirokazu Nagai:7, Yukio Kobayashi:8, Masayuki Shintani:9, Junjiro Saeki:9, Andrew Roberts:10, Paulo Maciag:10, Suresh K. Agarwal:10, Ahmed Hamed Salem:10, Kevin J. Freise:10, Tsukasa Kiriyama:9, Kensei Tobinai:8
1:Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 2:Department of Hematology and Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, 3:Department of Clinical Research and Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan, 4:Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 5:Department of Hematology, Toranomon Hospital, Minato-ku, Tokyo, Japan, 6:Department of Hematology, National Kyushu Cancer Center Hospital, Fukuoka, Japan, 7:Department of Hematology, National Hospital Organization Nagoya Medical Center, Aichi, Japan, 8:Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 9:AbbVie GK, Tokyo, Japan, 10:AbbVie Inc., North Chicago, IL, USA

Identification of IRAK-M as a key molecule in the pathogenesis of chronic lymphocytic leukemia

[演者] Yoshikane Kikushige (菊繁 吉謙):1
[著者] Toshihiro Miyamoto (宮本 敏浩):2, Koichi Akashi (赤司 浩一):2
1:Dept. of Medicine and Biosystemic Sciences, Kyushu University, Fukuoka, Japan, 2:Kyushu University, Fukuoka, Japan

Ibrutinib (Ibr) in untreated patients ≥65 with chronic lymphocytic leukemia (CLL): Updated data

[演者] Peter Hillmen:1
[著者] Paul Barr:2, Tadeusz Robak:3, Carolyn Owen:4, Alessandra Tedeschi:5, Osnat Bairey:6, Nancy Bartlett:7, Steven Coutre:8, Lori Styles:9, Paolo Ghia:10
1:The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK, 2:University of Rochester Medical Center, Rochester, NY, USA, 3:Medical University of Lodz, Poland, 4:Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada, 5:ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, 6:Rabin Medical Center, Beilinson Campus, Petah Tikvah, Israel, 7:Washington University School of Medicine, St. Louis, MO, USA, 8:Stanford University School of Medicine, Stanford, CA, USA, 9:Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA, 10:L’Università Vita-Salute San Raffaele Ospedale-Milano, Milan, Italy

First line Bendamustine plus Rituximab in chronic lymphocytic leukemia. The MDA-CLL-2015-02 study

[演者] Adolfo de la Fuente:1
[著者] Maria Jose Terol:2, Begona Navas:3, Antonio Gutierrez:4, Marta Callejas:5, Jose Antonio Garcia Marco:6, Maria Dolores Garcia-Malo:7, Javier de la Serna:8, Isabel Gonzalez Gascon y Marin:9, Laura Garcia Sanchis:10, Monica Ballesteros:11, Celina Benavente:12, Isidro Jarque:13, Juliana Ochoa Gullon:12, Paola Beneit:14, Raquel de Ona:1, Carlos Montalban:1, Monica Estevez:1, Rebeca Iglesias:1, Antonio Diaz-Lopez:15, Patricia Baltasar:16
1:MD Anderson CC, Spain, 2:H. Clinico de Valencia, 3:H. U. Moncloa Madrid, 4:H. Son espases Palma de Mallorca, 5:H. U. Principe de Asturias Alcala de Henares Madrid, 6:H. U. Puerta de Hierro Madrid, 7:H. U. Morales Meseguer Murcia, 8:H. U. 12 de Octubre Madrid, 9:H. Infanta Leonor Madrid, 10:H. General de Castellon, 11:H. G. U. Gregorio Maranon, 12:H. Clinico san Carlos, 13:H. U. Politecnico La Fe de Valencia, 14:H. San Juan de Alicante, 15:Fundacion MD Anderson Madrid, 16:H. U. La Paz

Chronic lymphocytic leukemia/small lymphocytic lymphoma with 11q deletion

[演者] Tomoko Yamashita (山下 知子):1
[著者] Hiroki Tsutsumi (堤 大樹):1, Kota Yoshifuji (吉藤 康太):1, Tatsuya Saito (齊藤 達也):1, Yoshihiro Umezawa (梅澤 佳央):1, Ayako Nogami (野上 彩子):1, Ken Watanabe (渡邉 健):1, Toshikage Nagao (長尾 俊景):1, Masahide Yamamoto (山本 正英):1, Chizuko Sakashita (坂下 千瑞子):1, Ayako Arai (新井 文子):1, Norihiko Kawamata (川又 紀彦):1, Osamu Miura (三浦 修):1, Tetsuya Fukuda (福田 哲也):1
1:Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan

詳細検索